Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Compound made by gut bacteria from ellagitannins in pomegranate and walnuts, and sold ready-made (for example Mitopure) because not everyone's gut bacteria produce it. Trials show it changes mitochondrial and inflammation markers in people; effects on muscle strength and endurance are mixed, and the two main trials in middle-aged and older adults missed their primary endpoints.
8 of 14 results reported a benefit, from 2 published studies.
2 randomised trials
The larger 4-month trial in middle-aged adults missed its main measure, peak power output. The strength gains shown are its secondary measures and an 8-week trial of 20 male athletes.
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultMuscular force production. Influenced by training, protein intake, hormones, and neuromuscular efficiency.
Also known as: UA, Mitopure
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for Urolithin A in strength.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Be the first to share what you noticed with Urolithin A for strength. Why counts start empty.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 39487653 2024 | Randomised trial | twenty | 8-week | 1RM bench press | 3.50 ± 0.79 kg (p = 0.462) | No benefit |
| PMID 39487653 2024 | Randomised trial | twenty | 8-week | 1RM squat | 2.55 ± 1.36 kg (p = 0.710) | No benefit |
| PMID 39487653 2024 | Randomised trial | twenty | 8-week | 3-methylhistidine (3-MH) | -3.20 ± 0.31 μmol/L (p = 0.36) | No benefit |
| PMID 39487653 2024 | Randomised trial | twenty | 8-week | C-reactive protein (CRP) | -0.79 ± 0.38 mg/L (p = 0.032) | Benefit |
| PMID 39487653 2024 | Randomised trial | twenty | 8-week | Interleukin-6 (IL-6) | -1.75 ± 0.45 pg/mL (p = 0.215) | No benefit |
| PMID 39487653 2024 | Randomised trial | twenty | 8-week | Maximum Voluntary Isometric Contraction (MVIC) | 43.50 ± 0.77 NM (p = 0.048) | Benefit |
| PMID 39487653 2024 | Randomised trial | twenty | 8-week | repetitions to failure (RTF) | 2.00 ± 1.22 (p = 0.011) | Benefit |
| PMID 39487653 2024 | Randomised trial | twenty | 8-week | superoxide dismutase (SOD) | -4.32 ± 0.90 U/mL (p = 0.041) | Unclear |
| PMID 35584623 2022 | Randomised trial | - | 4 months | aerobic endurance (peak oxygen consumption [VO2]) | reported qualitatively | Benefit |
| PMID 35584623 2022 | Randomised trial | - | 4 months | expression of proteins linked to mitophagy and mitochondrial metabolism in skeletal muscle | reported qualitatively | Benefit |
| PMID 35584623 2022 | Randomised trial | - | 4 months | muscle strength | ∼12% | Benefit |
| PMID 35584623 2022 | Randomised trial | - | 4 months | peak power output | reported qualitatively | No benefit |
| PMID 35584623 2022 | Randomised trial | - | 4 months | physical performance (6 min walk test) | reported qualitatively | Benefit |
| PMID 35584623 2022 | Randomised trial | - | 4 months | plasma acylcarnitines and C-reactive proteins | reported qualitatively | Benefit |